- Company Pursues Strategy of Reducing Heart Attack Deaths by Shielding High-Risk Plaques in Coronary Arteries
—
DOYLESTOWN, Pennsylvania, May 8DOYLESTOWN, Pennsylvania, May 8 /PRNewswire/ -- Prescient Medical, Inc., a privately held medical device company dedicated to reducing deaths from heart attacks, will present new experimental results on the chemical characterization and treatment of rupture-prone or "vulnerable" plaques, with a focus on the vPredict(TM) Optical Catheter System and the vProtect(TM) Luminal Shield, at the upcoming EuroPCR 2008 conference to be held in Barcelona, Spain from May 13 to 16.
The vProtect Luminal Shield was designed by Prescient Medical to treat soft, atherosclerotic lesions that may be at risk of rupture or that have recently ruptured. The self-expanding design of vProtect is a departure from the balloon-expandable stents that are mainstays of current focal treatment for coronary artery disease (CAD). The vProtect Luminal Shield has been designed to limit complications commonly associated with the insertion of stents, including vessel injury, restenosis, neointimal hyperplasia, and thrombosis.
The presentations will be an integral part of a session entitled "Glimpse Into The Future: Current Understanding of High-Risk Atherosclerosis Coronary Lesions," which will be held on May 14, 2008 from 13:30 to 16:50 in Room 5 of the conference. Professor Patrick Serruys, head of the Erasmus Medical Center's Department of Interventional Cardiology, will co-chair the session, which features presentations from leading authorities on coronary artery disease, including Dr. Guillermo Tearney, a distinguished researcher on the development and validation of new optical diagnostic technologies at Massachusetts General Hospital; and Dr. Juan Granada, Medical Director at the Jack H. Skirball Center for Cardiovascular Research. Dr. Tearney will present results from Prescient's vPredict Optical Catheter System in his presentation, "Spectroscopy Imaging of Coronary Lesions: Compositional Assessment". Dr. Granada will reveal the latest results obtained with the vProtect Luminal Shield in "Shielding for High-Risk Plaque."
Prescient Medical is dedicated to providing interventional cardiologists with new methods for effectively addressing different plaque types through enhanced conformability and adaptability of the Shield device to vessel structure, morphology, and dynamic forces. According to Dr. Granada, vProtect represents a revolutionary departure from the use of rigid balloon-expandable stents for coronary artery disease: "The vProtect Luminal Shield is the first step toward the goal of creating products that will achieve plaque stabilization and promote vascular healing. Prescient Medical has designed this device to conform to the physiology of the coronary arteries, rather than force the arteries to conform to a rigid metal scaffold."
For more information on Prescient Medical or its products, as well as the presentations of Professor Serruys, Dr. Tearney, or Dr. Granada, please contact Ilana Odess, General Manager of Prescient Medical, at +1-917-941-9990. Ms. Odess will be available to meet with representatives of the medical community throughout the conference at the Rafael Hoteles Diagonal Port, Estrellas, C/Lope de Vega, 4, 08005, 34-932-302 000- Suite Clave (201).
About Prescient Medical, Inc.
Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at www.prescientmedical.com or call +1-866-376-0500.
Web site: http://www.prescientmedical.com
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
